VPA-985 IN PATIENTS WITH HYPONATREMIA

VPA-985 用于低钠血症患者

• 批准号: 6276556
• 负责人: MARC THIBONNIER
• 金额: $ 1.83万
• 依托单位: CASE WESTERN RESERVE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-12-01 至 1998-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6276556
• 关键词: blood pressure; blood volume; cell proliferation; clinical research; clinical trial phase I; congestive heart failure; diuresis; drug screening /evaluation; homeostasis; human subject; human therapy evaluation; hyponatremia; liver cirrhosis; nephrotic syndrome; osmotic pressure; pharmacokinetics; second messengers; secretin; secretion; vasopressins

Vasopressin (AVP) is a peptide hormone actively involved in the regulatin of body fluid osmolality, blood volume, blood pressure, and cell prliferation via the stimulation of specific membrane-bound receptors classified into pituitary subtypes having distinct pharmacological profiles and intracellular second messengers. The secretion of AVP is an absolute requirement for the maintenacne of fluid homeostasis. An agent that increases urine output by producing a free water diuresis would be a significant advantage in conditions such as hyponatremia of congestive heart failure, liver chirrhosis, nephrotic syndrome and the syndrome of inappropriate secretin of antidiuretic hormone (SIADH). This study is designed to evaluate the effecacy, safety, and tolerance of VPA-985, a selective non-peptidic orally active AVP antagonist, in patients with hyponatremia due to drug induced SIADH. Preliminary pharmacokinetic and pharmacodynamic parameters will be asessed.

血管加压素（AVP）是一种肽类激素，其积极参与了 调节体液渗透压、血容量、血压和 细胞增殖通过刺激特定的膜结合 受体分为垂体亚型， 药理学特征和细胞内第二信使。 的 AVP的分泌是维持体液平衡的必要条件 体内平衡 利尿剂一种通过产生一种游离的 在以下情况下，水利尿将具有显着优势 充血性心力衰竭、肝硬化、肾病低钠血症 抗利尿激素分泌不当综合征 激素（SIADH）。本研究旨在评价其有效性， VPA-985（一种选择性非肽口服活性物质）的安全性和耐受性 AVP拮抗剂，用于药物诱导的低钠血症患者 SIADH。 初步药代动力学和药效学参数将 被评估。